AVDL - Avadel Pharmaceuticals plc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.514B

Cash

88.79M

Avg Qtr Burn

-32.0M

Short % of Float

12.64%

Insider Ownership

4.71%

Institutional Own.

78.59%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LUMRYZ (FT218) Details Solid tumor/s, Melanoma, Narcolepsy, Excessive daytime sleepiness, Cataplexy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (FT218) Details Excessive daytime sleepiness, Narcolepsy	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUMRYZ (FT218) Details EDS in Idiopathic Hypersomnia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.